Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...
Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...
Researchers have unveiled innovative, label-free ratiometric fluorosensor designed for the selective and sensitive detection of enteroviral RNA. The research promises to deliver even more advanced and ...
Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB ... s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated ...
In a significant advancement, researchers from the Nanoscience Center (NSC) at the University of Jyväskylä, Finland, have ...
Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback